Key decision-making factors for human papillomavirus (HPV) vaccine program introduction in low-and-middle-income-countries: Global and national stakeholder perspectives

Hum Vaccin Immunother. 2022 Dec 30;18(7):2150454. doi: 10.1080/21645515.2022.2150454. Epub 2022 Dec 9.

Abstract

Low-and-middle-income countries (LMICs) experience a high burden of cervical cancer. The human papillomavirus (HPV) vaccine prevents high-risk strains of HPV that cause cervical cancer; however, the integration of HPV vaccines into national immunization programs within many LMICs has been suboptimal. Our study evaluated key factors that drive the decision-making process for the implementation of HPV vaccine programs in LMICs. Stakeholder analysis and semi-structured in-depth interviews were conducted with national and global stakeholders. Interview data were analyzed through qualitative descriptive methods. Findings from our study revealed the decision-making process for HPV vaccines requires the involvement of multiple institutions and stakeholders from national and global levels, with decision-making being a country-specific process. Partner considerations, locally driven processes, availability of data, and infrastructure and resource considerations were found to be critical factors in the decision-making process. Future programs should evaluate the best approaches for investing in initiatives to enhance coordination, ensure vaccine introduction is locally driven, increase the availability of data needed for decision-making, and equip countries with the necessary resources to guide country decision-making in the face of increasingly complex decision-making environments.

Keywords: Decision-making; HPV; HPV vaccination decision-making; human papillomavirus vaccination; low-and-middle-income countries; policy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Human Papillomavirus Viruses
  • Humans
  • Immunization Programs
  • Papillomavirus Infections* / prevention & control
  • Papillomavirus Vaccines*
  • Uterine Cervical Neoplasms* / prevention & control
  • Vaccination

Substances

  • Papillomavirus Vaccines

Grants and funding

This work was supported by funding from the Bill and Melinda Gates Foundation, under INV-006006 (PI: Rupali Limaye, JHU). The funders had no role in the design and conduct of the study, nor the decision to prepare and submit the manuscript for publication